Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports

Open Access 22-09-2023 | Radiotherapy

Radiation Management for Breast Cancer After Neoadjuvant Therapy

Authors: Benjin D Facer, Ton Wang, Christina Weed, Ashley Pariser, Mathew Cherian, Kai C Johnson, Dionisia Quiroga, Daniel Stover, Samilia Obeng-Gyasi, Doreen Agnese, Bridget A Oppong, Sharad Goyal, Therese Andraos, Sasha Beyer, Sachin R Jhawar

Published in: Current Breast Cancer Reports

Login to get access

Abstract

Purpose of Review

Neoadjuvant chemotherapy (NAC) utilization is an important part of breast cancer therapy. Recent advances call into question the optimal role of radiotherapy after NAC, as many radiation studies were performed without NAC. This review was conducted to understand the current data, outstanding questions and ongoing trials related to radiotherapy after NAC.

Recent Findings

Response to NAC is associated with promising clinical outcomes, particularly in triple-negative and HER2+ breast cancer. Retrospective data suggest that modification of radiotherapy based on tumor response to NAC may be appropriate, though caution is advised without prospective randomized evidence. NSABP B-51 and Alliance A011202 will investigate the management of nodal disease in this setting. Future trials will examine the optimal sequencing of treatments.

Summary

The personalization of adjuvant radiotherapy based on response to neoadjuvant chemotherapy is an attractive goal that is currently being evaluated in multiple clinical trials, including NSABP B-51.
Literature
1.
2.
Aquina CT, Ejaz A, Tsung A, Pawlik TM, Cloyd JM. National trends in the use of neoadjuvant therapy before cancer surgery in the US from 2004 to 2016. JAMA Network Open. 2021;4(3):e211031. PubMedPubMedCentralCrossRef
3.
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. JNCI Monographs. 2001;2001(30):96–102. CrossRef
4.
Volders JH, Negenborn VL, Spronk PE, et al. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018;168(1):1–12. PubMedCrossRef
5.
Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. New Engl J Med. 2021;384(25):2394–405. PubMedCrossRef
6.
Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New Engl J Med. 2017;376(22):2147–59. PubMedCrossRef
7.
I-SPY2 Trial Consortium. Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020;6(9):1355–62. CrossRef
8.
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. PubMedCrossRef
9.
Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. JCO. 1996;14(5):1558–64.
10.
Fisher B, Anderson S, Bryant J, et al. Twenty-Year Follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med. 2002;347(16):1233–41. PubMedCrossRef
11.
Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr. 1992;11:19–25.
12.
13.
Mamounas EP, NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Williston Park). 1997;11(6 Suppl 6):37–40. PubMed
14.
Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. JCO. 2003;21(22):4165–74. CrossRef
15.
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. JCO. 2008;26(5):778–85. CrossRef
16.
Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6. PubMedPubMedCentralCrossRef
17.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast V.4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved.
18.
Veronesi U, Zucali R, Luini A. Local control and survival in early breast cancer: the Milan trial. Int J Radiat Oncol Biol Phys. 1986;12(5):717–20. PubMedCrossRef
19.
Sarrazin D, Lê M, Rouëssé J, et al. Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less. The experience of the Institut Gustave-Roussy. Cancer. 1984;53(5):1209–13. PubMedCrossRef
20.
Poortmans PM, Weltens C, Fortpied C, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21(12):1602–10. PubMedCrossRef
21.
22.••
Marks LB, Prosnitz LR. Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves? J Clin Oncol. 2014;32(6):491–3. https://​doi.​org/​10.​1200/​JCO.​2013.​51.​3523.  An excellent commentary offering caution regarding the omission of radiotherapy in a patient cohort that may actually derive the most clinical benefit.
23.
24.
Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet Oncology. 2013;14(12):1183–92. PubMedCrossRef
25.
Mailhot Vega RB, Wang S, Brooks ED, et al. Evaluating regional nodal irradiation allocation and association with oncologic outcomes in NSABP B-18, B-27, B-40, and B-41. Int J Radiat Oncol Biol Phys. 2022;113(3):542–51. PubMedCrossRef
26.•
de Wild SR, de Munck L, Simons JM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022;23(9):1201–10. Modifying the radiation approach based on risk status after NAC did not worsen clinical outcomes. This serves as justification for a personalized approach to RT in many settings. PubMedCrossRef
27.••
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013;310(14):1455–61. De-escalating surgery from ALND to SNLB is a major advancement. This study identifies patients that may achieve the benefits of SNLB without losing out on the benefits of ALND. PubMedPubMedCentralCrossRef
28.
Haffty BG, McCall LM, Ballman KV, et al. Impact of radiation on locoregional control in women with node-positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: results from ACOSOG Z1071 clinical trial. Int J Radiat Oncol Biol Phys. 2019;105(1):174–82. PubMedPubMedCentralCrossRef
29.
Kyndi M, Overgaard M, Nielsen HM, et al. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009;90(1):74–9. PubMedCrossRef
30.
Stecklein SR, Park M, Liu DD, et al. Long-term impact of regional nodal irradiation in patients with node-positive breast cancer treated with neoadjuvant systemic therapy. Int J Radiat Oncol Biol Phys. 2018;102(3):568–77. PubMedCrossRef
31.••
Mamounas EP, Bandos H, White JR, et al. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). J Clin Oncol. 2019;37(15_suppl):TPS600–TPS600. This trial will give randomized, prospective data regarding axillary nodal irradiation in the setting of cN+, ypN0 disease. The most appropriate radiation strategy is currently unknown.
32.•
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01901094, Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. 2013. Available from: https://​classic.​clinicaltrials.​gov/​ct2/​show/​NCT01901094. An ongoing trial examining if ALND can be omitted in favor of radiotherapy in the setting of ypN+ disease.
33.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.
34.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. PubMedCrossRef
35.
von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive her2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. CrossRef
36.
Li Y-F, Chang L, Li W-H, et al. Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: a meta-analysis. The Breast. 2016;27:93–8. PubMedCrossRef
37.
Corbin KS, Breen WG, Strauss JB. Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1). Clin Transl Radiat Oncol. 2020;24:99–101. PubMedPubMedCentral
38.
Geraud A, Xu HP, Beuzeboc P, Kirova YM. Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. J Neurooncol. 2017;131(1):69–72. PubMedCrossRef
39.
Sherry AD, Mayer IA, Ayala-Peacock DN, et al. Combining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: feasibility, safety, and toxicity. Clin Breast Cancer. 2020;20(4):344–352.e1. PubMedCrossRef
40.
Woodward WA, Fang P, Arriaga L, et al. A phase 2 study of preoperative capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):777–83. PubMedPubMedCentralCrossRef
41.
Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4(4):1013–9. PubMed
42.
Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. New Engl J Med. 2022;386(6):556–67. PubMedCrossRef
43.
Jahan N, Rehman S, Meda S, Tijani L. Abstract P5-18-14: The relative risk of pneumonitis associated with neoadjuvant chemoimmunotherapy use in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Cancer Res. 2022;82(4_Supplement):18–4.
44.
45.
Bosacki C, Bouleftour W, Sotton S, et al. CDK 4/6 inhibitors combined with radiotherapy: a review of literature. Clin Transl Radiat Oncol. 2021;26:79–85. PubMed
46.
47.
48.
Loap P, Loirat D, Berger F, et al. Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial. JAMA Oncol. 2022;8(12):1802–8. PubMedCrossRef
49.
Chopra N, Tovey H, Pearson A, et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun. 2020;11(1):2662. PubMedPubMedCentralCrossRef
50.
Michmerhuizen AR, Pesch AM, Moubadder L, et al. PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation. Mol Cancer Ther. 2019;18(11):2063–73. PubMedPubMedCentralCrossRef
51.
52.
53.
Kuerer HM, Rauch GM, Krishnamurthy S, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg. 2018;267(5):946–51. PubMedCrossRef
54.
Basik M, Cecchini RS, Santos JFDL, et al. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Cancer Res. 2020;80(4_Supplement):GS5–05. CrossRef
55.
Kuerer HM, Smith BD, Krishnamurthy S, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022;23(12):1517–24. PubMedCrossRef
56.
Cullinane C, Fleming C, O’Leary DP, et al. Association of circulating tumor dna with disease-free survival in breast cancer: a systematic review and meta-analysis. JAMA Network Open. 2020;3(11):e2026921. PubMedPubMedCentralCrossRef
57.
Cailleux F, Agostinetto E, Lambertini M, et al. Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO Precis Oncol. 2022;6:e2200148. PubMedCrossRef
58.
Magbanua MJM, Swigart LB, Wu H-T, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229–39. PubMedCrossRef
Metadata
Title
Radiation Management for Breast Cancer After Neoadjuvant Therapy
Authors
Benjin D Facer
Ton Wang
Christina Weed
Ashley Pariser
Mathew Cherian
Kai C Johnson
Dionisia Quiroga
Daniel Stover
Samilia Obeng-Gyasi
Doreen Agnese
Bridget A Oppong
Sharad Goyal
Therese Andraos
Sasha Beyer
Sachin R Jhawar
Publication date
22-09-2023
Publisher
Springer US
Published in
Current Breast Cancer Reports
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-023-00506-1

European Society for Medical Oncology Congress 2023

NSCLC Video

ESMO23: Non-small-cell lung cancer highlights

Watch the panel discussion

Dr. Luis Paz-Ares, Prof. Solange Peters and Dr. Marina Garassino provide their insights on the latest findings from the following pivotal phase III trials: ALINA, CheckMate-77T, LIBRETTO-431, and MARIPOSA-1 and -2.

Supported by: F. Hoffmann-La Roche Ltd.
Dr. Luis Paz-Ares
Prof. Solange Peters
Dr. Marina Garassino

ESMO23: Small-cell lung cancer highlights

SCLC Expert Interview

Cancer of Unknown Primary: Key results from ESMO 2023

Cancer of Unknown Primary Expert Interview

Tisotumab vedotin improves recurrent and metastatic cervical cancer survival

25-10-2023 Cervical Cancer News

EV-302 heralds practice change for advanced urothelial cancer

24-10-2023 Urothelial Cancer News

First-line selpercatinib supported for RET-mutant medullary thyroid cancer

23-10-2023 Thyroid Cancer News

» View more highlights on the ESMO 2023 hub page

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

45/♀ with increasing weakness, loss of appetite, diarrhoea and oedema – Case 29

Case-Based Insights: Oncology and Hematology Training Course
Course icon
0 Points

A 45-year-old female patient complains that she has been getting weaker and weaker for several months. She has no appetite and suffers from diarrhoea. Immunofixation shows monoclonal lambda light chains in the serum. What is your tentative diagnosis?

48/♀ with increasing spontaneous haematomas all over her body – Case 37

Case-Based Insights: Oncology and Hematology Training Course
Course icon
0 Points

A 48-year-old female patient feels listless and reports petechiae occurred for the first time. In the last 3 days, she had reportedly developed severe toothache and fever. The blood count shows severe pancytopenia. What are your first steps?

49/♀ with lymphoedema of the arm in condition of metastasised triple-negative breast carcinoma – Case 43

Case-Based Insights: Oncology and Hematology Training Course
Course icon
0 Points

The 49-year-old female patient presents with significant swelling of the right arm. She reports having been diagnosed with breast cancer 1½ years ago, followed by surgical removal of the tumour. She had then received chemotherapy and irradiation. How do you proceed?

53/♂ with movement-dependent pain in the left anterior pelvis and bloody urine – Case 39

Case-Based Insights: Oncology and Hematology Training Course
Course icon
0 Points

A 53-year-old man complains of increasing pain in the left anterior pelvis, which is described as movement-dependent with radiation into the left lower extremity. For several months, he had noticed bloody urine from time to time without pain during micturition. What are your suspicions?

Image Credits